The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Abstract
Background Excitotoxic damage due to excess release of neuronal glutamate is hypothesized to play a pivotal role in the pathogenesis of focal cerebral ischemia. Drugs that antagonize excitatory amino acid function are consistently neuroprotective in preclinical models of stroke, and many are now entering clinical trials. Summary Antagonists of the N-methyl-d-aspartate (NMDA) receptor are furthest advanced in clinical development for stroke. Both noncompetitive (aptiganel hydrochloride, dextrorphan) and competitive (selfotel,d-CPPene) antagonists have undergone tolerability studies in acute stroke and traumatic brain injury. These agents all cause a similar spectrum of neuropsychological symptoms, and several have important cardiovascular effects. Other modulatory sites on the NMDA receptor complex, notably the polyamine and magnesium ion sites, are also the subject of clinical trials. Glycine site antagonists are in early clinical development. Non-NMDA glutamate receptor antagonists remain in preclinical study. Neuroprotection by agents that block glutamate release in vitro may be due to sodium channel blockade in vivo, but some agents (619C89) exhibit neurological effects similar to NMDA antagonists in stroke. The therapeutic index is unknown for different drugs but may be determined by cardiovascular effects, especially hypotension, which may be detrimental after stroke. Conclusions Excitatory amino acid antagonists are in advanced development in the treatment of stroke and traumatic brain injury. A similar pattern of side effects is apparent with the majority of agents. However, cardiovascular effects may ultimately define therapeutic index for each drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Ketamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Kainic acid as a tool in neurobiology
McGeer, E. G., Olney, J. W., & McGeer, P. L. (1978) · Raven Press eBooks · Cited by 1,308
Pathological Changes Induced in Cerebrocortical Neurons by Phencyclidine and Related Drugs
Olney, J. W., Labruyere, J., & Price, M. T. (1989) · Science · doi:10.1126/science.2660263 · Cited by 1,237
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 961
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death
Rothman, S. (1984) · The Journal of Neuroscience · doi:10.1523/jneurosci.04-07-01884.1984 · Cited by 884
NMDA Antagonist Neurotoxicity: Mechanism and Prevention
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991) · Science · doi:10.1126/science.1835799 · Cited by 841
Glutamate neurotoxicity in cortical cell culture is calcium dependent
Choi, D. W. (1985) · Neuroscience Letters · doi:10.1016/0304-3940(85)90069-2 · Cited by 810
Ketamine: an update on the first twenty-five years of clinical experience
Reich, D. L., & Silvay, G. (1989) · Canadian Journal of Anaesthesia · doi:10.1007/bf03011442 · Cited by 708
Chen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
Neurotoxicity of excitatory amino acids
Guidotti, A. (1990) · Raven Press eBooks · Cited by 617
Alternative excitotoxic hypotheses
Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574
The glutamate antagonist MK‐801 reduces focal ischemic brain damage in the rat
Park, C. K., Nehls, D. G., Graham, D. I., Teasdale, G. M., & McCulloch, J. (1988) · Annals of Neurology · doi:10.1002/ana.410240411 · Cited by 539
The glycine site of the NMDA receptor — five years on
Kemp, J. A., & Leeson, P. D. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90108-v · Cited by 436
Progressive Derangement of Periinfarct Viable Tissue in Ischemic Stroke
Heiss, W.-D., Huber, M., Fink, G. R., Herholz, K., Pietrzyk, U., Wagner, R., & Wienhard, K. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.29 · Cited by 433
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Protective Effect of the Glutamate Antagonist, MK-801 in Focal Cerebral Ischemia in the Cat
Ozyurt, E., Graham, D. I., Woodruff, G. N., & McCulloch, J. (1988) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1988.18 · Cited by 368
Noncompetitive excitatory amino acid receptor antagonists
Lodge, D., & Johnson, K. M. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90323-z · Cited by 355
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
Bormann, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90385-3 · Cited by 351
Response of chronic neuropathic pain syndromes to ketamine: a preliminary study
Backonja, M., Arndt, G., Gombar, K. A., Check, B., & Zimmermann, M. (1994) · Pain · doi:10.1016/0304-3959(94)90149-x · Cited by 312
Kristensen, J. D., Svensson, B., & Gordh, T. (1992) · Pain · doi:10.1016/0304-3959(92)90266-e · Cited by 301
Wahlgren, N. G., MacMahon, D. G., De Keyser, J., Indredavik, B., & Ryman, T. (1994) · Cerebrovascular Diseases · doi:10.1159/000108483 · Cited by 279
N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?
Albers, G. W., Goldberg, M. P., & Choi, D. W. (1989) · Annals of Neurology · doi:10.1002/ana.410250412 · Cited by 272
Fix, A. S., Horn, J. W., Wightman, K. A., Johnson, C. A., Long, G. G., Storts, R. W., Farber, N., Wozniak, D. F., & Olney, J. W. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1153 · Cited by 256
Lipton, S. A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90198-u · Cited by 256
Park, C. K., Nehls, D. G., Graham, D. I., Teasdale, G. M., & McCulloch, J. (1988) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1988.124 · Cited by 244
Sharp, F. R., Jasper, P., Hall, J., Noble, L., & Sagar, S. M. (1991) · Annals of Neurology · doi:10.1002/ana.410300609 · Cited by 235
Marchal, G., Rioux, P., Petit-Tabou, M. C., Derlon, J. M., Baron, J. C., Serrati, C., Viader, F., de la Sayette, V., Le Doze, F., Lochon, P., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91214-7 · Cited by 230
Foster, A. C., & Fagg, G. E. (1987) · Nature · doi:10.1038/329395a0 · Cited by 209
Greene, J. G., Porter, R. H. P., Eller, R. V., & Greenamyre, J. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03634.x · Cited by 208
Miller, B. L., Chang, L., Mena, I., Boone, K., & Lesser, I. M. (1993) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000107324 · Cited by 206
Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans
Baker, A. J., Moulton, R. J., MacMillan, V. H., & Shedden, P. M. (1993) · Journal of Neurosurgery · doi:10.3171/jns.1993.79.3.0369 · Cited by 204
Dextromethorphan and neuromodulation: old drug coughs up new activities
Tortella, F. C., Pellicano, M., & Bowery, N. G. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90050-3 · Cited by 202
A STUDY OF A 1-ARYL CYCLO HEXYL AMINE FOR ANESTHESIA*
GREIFENSTEIN, F. E., DeVAULT, M., YOSHITAKE, J., & GAJEWSKI, J. E. (1958) · Anesthesia & Analgesia · doi:10.1213/00000539-195809000-00007 · Cited by 202
Oxygen free radicals regulate NMDA receptor function via a redox modulatory site
Aizenman, E., Hartnett, K. A., & Reynoldst, I. J. (1990) · Neuron · doi:10.1016/0896-6273(90)90343-e · Cited by 201
Albers, G. W., Atkinson, R. P., Kelley, R. E., & Rosenbaum, D. M. (1995) · Stroke · doi:10.1161/01.str.26.2.254 · Cited by 195
Sofia, R. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360423 · Cited by 194
Glutamate‐Mediated Injury in Focal Cerebral Ischemia: The Excitotoxin Hypothesis Revised
Hossmann, K. (1994) · Brain Pathology · doi:10.1111/j.1750-3639.1994.tb00808.x · Cited by 192
Rho, J. M., Donevan, S. D., & Rogawski, M. A. (1994) · Annals of Neurology · doi:10.1002/ana.410350216 · Cited by 187
BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage.
Leach, M. J., Swan, J. H., Eisenthal, D., Dopson, M., & Nobbs, M. (1993) · Stroke · doi:10.1161/01.str.24.7.1063 · Cited by 174
BULLOCK, R., ZAUNER, A., MYSEROS, J. S., MARMAROU, A., WOODWARD, J. J., & YOUNG, H. F. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb16586.x · Cited by 161
Neuroprotective effect of memantine demonstrated in vivo and in vitro
el Nasr, M. S., Peruche, B., Roβberg, C., Mennel, H.-D., & Krieglstein, J. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90206-l · Cited by 159
McCulloch, J. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04118.x · Cited by 141
Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
Rabey, J. M., Nissipeanu, P., & Korczyn, A. D. (1992) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260076 · Cited by 140
Status of Ketamine in Anesthesiology.
Domino, E. F. (1992) · Plastic & Reconstructive Surgery · doi:10.1097/00006534-199201000-00041 · Cited by 140
Bubser, M., Keseberg, U., Notz, P., & Schmidt, W. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90288-f · Cited by 138
SERNYL (C1-395) IN CLINICAL ANAESTHESIA
Johnstone, M., EVANS, V., & BAIGEL, S. (1959) · British Journal of Anaesthesia · doi:10.1093/bja/31.10.433 · Cited by 126
Görtelmeyer, R., & Erbler, H. C. (1992) · PubMed · Cited by 121
Lundy, P. M., LOCKWOOD, P. A., Thompson, G., et al. (1986) · Anesthesiology · doi:10.1097/00000542-198603000-00010 · Cited by 115
Dextromethorphan and dextrorphan as calcium channel antagonists
Carpenter, C. L., Marks, S. S., Watson, D. L., & Greenberg, D. A. (1988) · Brain Research · doi:10.1016/0006-8993(88)91497-7 · Cited by 114
Rock, M. J., ROCHA, S. R. D. L., L'Hommedieu, C. S., & Truemper, E. J. (1986) · Critical Care Medicine · doi:10.1097/00003246-198605000-00019 · Cited by 99
PCP (phencyclidine), historical and current perspectives
Domino, E. F. (1981) · Medical Entomology and Zoology · Cited by 88
Hargreaves, R. J., Rigby, M., Smith, D. W., & Hill, R. G. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13768.x · Cited by 87
Bullock, R., Graham, D. I., Swanson, S., & McCulloch, J. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.57 · Cited by 84
Hargreaves, R. J., Rigby, M., Smith, D. W., Hill, R. G., & Iversen, L. L. (1993) · Neurochemical Research · doi:10.1007/bf00975046 · Cited by 79
Kurumaji, A., & McCulloch, J. (1989) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1989.112 · Cited by 74
Development of Tolerance to Ketamine in an Infant Undergoing Repeated Anesthesia
Byer, D. E., & Gould, A. B. (1981) · Anesthesiology · doi:10.1097/00000542-198103000-00016 · Cited by 72
Pharmacotoxic psychosis after memantine in Parkinson's disease
Riederer, P. F., Lange, K. W., Kornhuber, J., & Danielczyk, W. (1991) · The Lancet · doi:10.1016/0140-6736(91)91888-2 · Cited by 69
Memantine in the treatment of senile dementia of the Alzheimer type
Fleischhacker, W. W., Buchgeher, A., & Schubert, H. (1986) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(86)90047-3 · Cited by 68
Torp, R., Arvin, B. M., Peillet, E. L., Chapman, A. G., Ottersen, O. P., & Meldrum, B. S. (1993) · Experimental Brain Research · doi:10.1007/bf00234106 · Cited by 67
Ketamine–Can Chronic Use Impair Memory
Jansen, K. L. R. (1990) · International Journal of the Addictions · doi:10.3109/10826089009056204 · Cited by 66
Prophylactic neuroprotection for cerebral ischemia.
Fisher, M., Jonas, S., Sacco, R. L., et al. (1994) · Stroke · doi:10.1161/01.str.25.5.1075 · Cited by 65
Evaluation of a competitive NMDA antagonist ( D ‐CPPene) in feline focal cerebral ischemia
Chen, M., Bullock, R. M., Graham, D. I., Frey, P. A., Lowe, D., & McCulloch, J. (1991) · Annals of Neurology · doi:10.1002/ana.410300112 · Cited by 63
Chapter 8 Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia
Pulsinelli, W. A., Sarokin, A., & Buchan, A. M. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)63262-8 · Cited by 60
Pharmacological effects of the non‐competitive NMDA antagonist CNS 1102 in normal volunteers.
Muir, K. W., Grosset, D. G., Gamzu, E., & Lees, K. R. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04318.x · Cited by 54
Self-citationLekieffre, D., & Meldrum, B. S. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90565-w · Cited by 54
Foster, A. C., Willis, C. L., & Tridgett, R. (1990) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1990.tb00418.x · Cited by 50
Duval, D., Roome, N. O., Gauffeny, C., Nowick, J. P., & Scatton, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90402-s · Cited by 49
Heart Rate and Blood Pressure Effects of Esmolol after Ketamine Induction and Intubation
Gold, M. I., Brown, M., Coverman, S., & Herrington, C. A. (1986) · Anesthesiology · doi:10.1097/00000542-198606000-00007 · Cited by 49
Doenicke, Α., Angster, R., Mayer, M., Adams, H. A., Grillenberger, G., & Nebauer, A. E. (1992) · PubMed · Cited by 39
Drug refractory epilepsy in brain damage: effect of dextromethorphan on EEG in four patients.
Schmitt, B., Netzer, R., Fanconi, S., Baumann, P., & Boltshauser, E. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.3.333 · Cited by 36
Cerebral arterial narrowing with nicotine patch
Jackson, M. C. (1993) · The Lancet · doi:10.1016/0140-6736(93)92323-l · Cited by 35
ARE THERE LONG-TERM EFFECTS OF KETAMINE ON THE CENTRAL NERVOUS SYSTEM?
Schorn, T. O. F., & WHITWAM, J. G. (1980) · British Journal of Anaesthesia · doi:10.1093/bja/52.10.967 · Cited by 29
Infusion analgesia for acute war injuries A comparison of pentazocine and ketamine
Bion, J. (1984) · Anaesthesia · doi:10.1111/j.1365-2044.1984.tb07362.x · Cited by 23
Reimherr, F. W., Wood, D. R., & Wender, P. H. (1986) · PubMed · Cited by 20
Grosset, D. G., Muir, K. W., & Lees, K. R. (1995) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199505000-00004 · Cited by 19
Self-citationMuir, K. W., Lees, K. R., Hamilton, S., George, C. F., Hobbiger, S. F., & Lunnon, M. W. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb16605.x · Cited by 18
Self-citationSexual disturbances during omeprazole therapy
Dutertre, J. P., Soutif, D., Jonville, A. P., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)91887-z · Cited by 17
Ketamine Hypertension and the Renin-Angiotensin System
Pipkin, F. B., & Waldron, B. A. (1983) · Clinical and Experimental Hypertension · doi:10.3109/10641968309081814 · Cited by 14
Lenzi, G. L., Padovani, A., Piero, V. D., Bragoni, M., Biasi, C. D., Altieri, M., Iannilli, M., Iacoboni, M., & Gualdi, G. F. (1994) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/s1052-3057(10)80100-4 · Cited by 12
WAGSTAFF, A., Teasdale, G. M., Clifton, G. L., & Stewart, L. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb16607.x · Cited by 9
Antagonism of the cardiovascular effects of ketamine by diazepam in volunteers.
ERDMANN, W., Pj, S., Agoston, S., & Langrehr, D. (1979) · PubMed · Cited by 6
Pedersen, T., & Hicquet, J. (1981) · PubMed · Cited by 2
Cited by
Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development
(1999) · Stroke · doi:10.1161/01.str.30.12.2752 · Cited by 1,251
Adams, H. P., Adams, R. J., Brott, T., del Zoppo, G. J., Furlan, A., Goldstein, L. B., Grubb, R. L., Higashida, R., Kidwell, C., Kwiatkowski, T. G., et al. (2003) · Stroke · doi:10.1161/01.str.0000064841.47697.22 · Cited by 1,245
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Metadata
- Authors
- Muir, K. W., & Lees, K. R.
- Venue
- Stroke
- Published
- 1995-03
- Volume
- 26
- Issue
- 3
- Pages
- 503-513
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2003066583
- Cited by
- 502
- References
- 88
- FWCI
- 45.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.